CompletedPhase 4NCT06690047
Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)
Studying Hereditary angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bernstein Clinical Research Center
- Principal Investigator
- Jonathan Bernstein, MDBernstein Clinical Research Center
- Intervention
- Ruconest(biological)
- Enrollment
- 5 enrolled
- Eligibility
- 14 years · All sexes
- Timeline
- 2018 – 2022
Study locations (2)
- Clinical Research Center of Alabama, Birmingham, Alabama, United States
- Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06690047 on ClinicalTrials.govOther trials for Hereditary angioedema
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07298447Donidalorsen Treatment in Children With Hereditary AngioedemaIonis Pharmaceuticals, Inc.
- RECRUITINGNANCT07559630Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidSJessica K. Stewart, MD
- RECRUITINGNCT07263685A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi ArabiaTakeda
- RECRUITINGPHASE3NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)ADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07251933A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesTakeda
- ENROLLING BY INVITATIONPHASE3NCT07204938A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGPHASE3NCT06960213STOP-HAE: A Phase 3 Study of ADX-324 in HAEADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07001280A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)CSL Behring